Amyloidosis Research Consortium, Inc.
Newton, MA
- UEI
- FNAUJA4K1198
- CAGE
- 7P9F7
- Primary NAICS
- Not on record
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Tax Exempt)
- SAM.gov registration date
- Physical address
- 320 Nevada St # 210, Newton, MA 02460, USA
- Website
- arci.org
- Founded
- 2015
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Health Care Equipment & Services
- Health Care Providers & Services
- Health & Wellness
- SIC code
- 83 Social Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
About the company
Amyloidosis Research Consortium, Inc. (ARC) is a 501(c)(3) non-profit organization established in 2015 as a patient-led nonprofit focused on accelerating the development, approval, and access to innovative treatments for amyloidosis. Registered in SAM.gov and located in Newton, Massachusetts, the organization specializes in building collaborative partnerships between government agencies, academia, industry, patients, and regulatory bodies to address critical barriers in medical research and drug development. ARC provides scientific research services and facilitates cross-stakeholder working groups aimed at advancing therapeutic solutions for rare, progressive protein misfolding diseases, with a specific focus on immunoglobulin light chain (AL) and transthyretin (ATTR) amyloidosis.
The organization has secured federal grant awards from agencies such as the National Institute on Aging and the National Center for Advancing Translational Sciences, with projects centered on advancing drug development through collaborative scientific initiatives. These grants have supported critical research efforts like the Amyloidosis Forum, a public-private partnership with the US Food and Drug Administration (FDA) designed to identify and bridge scientific gaps in drug discovery. Specific project objectives have included developing standardized imaging protocols, identifying prognostic factors, creating clinical endpoints, and accelerating access to data-driven insights from completed clinical trials. The grants typically involve hosting cross-stakeholder scientific meetings, conducting research to understand disease progression, and developing strategies to improve therapeutic development for complex, multi-systemic diseases that predominantly affect older adults. ARC's approach emphasizes collaborative research, leveraging expertise from diverse stakeholders to propel innovative approaches in rare disease treatment.
Quick answers
Is Amyloidosis Research Consortium, Inc. registered in SAM.gov?
Amyloidosis Research Consortium, Inc.'s SAM.gov registration expired on August 27, 2026.
What is Amyloidosis Research Consortium, Inc.'s most recent federal award?
Amyloidosis Research Consortium, Inc.'s most recent federal grant award is The amyloidosis forum: cross stakeholder working group projects to accelerate drug development in AL and attr… (R13AG096985), from National Institute on Aging (NIH), on September 1, 2025.
On GovTribe
See Amyloidosis Research Consortium, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors